These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31595343)

  • 1. A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma.
    Nagumo Y; Kojima T; Shiga M; Kandori S; Kimura T; Takaoka EI; Onozawa M; Miyazaki J; Kawai K; Ishikawa H; Sakurai H; Nishiyama H
    Int J Clin Oncol; 2020 Feb; 25(2):354-361. PubMed ID: 31595343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy.
    Krasnow RE; Drumm M; Roberts HJ; Niemierko A; Wu CL; Wu S; Zhang J; Heney NM; Wszolek MF; Blute ML; Feldman AS; Lee RJ; Zietman AL; Shipley WU; Efstathiou JA
    Eur Urol; 2017 Jul; 72(1):54-60. PubMed ID: 28040351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Histologic Subtypes on Clinical Outcomes After Radiation-Based Therapy for Muscle-Invasive Bladder Cancer.
    Halstuch D; Kool R; Marcq G; Breau RH; Black PC; Shayegan B; Kim M; Busca I; Abdi H; Dawidek MT; Uy M; Fervaha G; Cury FL; Alimohamed NS; Jeldres C; Rendon R; Brimo F; Siemens DR; Kulkarni GS; Kassouf W; Izawa JI
    J Urol; 2024 Nov; 212(5):710-719. PubMed ID: 39051515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
    Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
    J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
    Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
    Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
    Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
    Minato A; Noguchi H; Tomisaki I; Fukuda A; Kubo T; Nakayama T; Fujimoto N
    Cancer Control; 2018; 25(1):1073274818800269. PubMed ID: 30213195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squamous differentiation in patients with superficial bladder urothelial carcinoma is associated with high risk of recurrence and poor survival.
    Li G; Yu J; Song H; Zhu S; Sun L; Shang Z; Niu Y
    BMC Cancer; 2017 Aug; 17(1):530. PubMed ID: 28789622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
    Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital.
    Shah RB; Montgomery JS; Montie JE; Kunju LP
    Urol Oncol; 2013 Nov; 31(8):1650-5. PubMed ID: 22608543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of urine cytology in detecting histologic variants of urothelial carcinomas in the urinary bladder: Cytopathologic correlation of 72 cases.
    Yoo Y; Choi E; Lee DH; Park S; Sung SH
    Diagn Cytopathol; 2021 Mar; 49(3):367-373. PubMed ID: 33331144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy.
    Kijima T; Tanaka H; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    Clin Genitourin Cancer; 2020 Aug; 18(4):268-273.e2. PubMed ID: 31883941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urothelial Carcinoma In Situ of the Bladder With Glandular Differentiation: Report of 92 Cases.
    Yang Z; Epstein JI
    Am J Surg Pathol; 2018 Jul; 42(7):971-976. PubMed ID: 29683821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
    García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO
    World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal Trends and Cancer-Specific Mortality in Nonmetastatic Muscle-Invasive Urothelial Carcinoma of the Urinary Bladder Treated With Trimodal Therapy.
    de Angelis M; Scheipner L; Siech C; Jannello LMI; Baudo A; Bello FD; Goyal JA; Vitucci K; Tian Z; Longo N; Ahyai S; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Gandaglia G; Moschini M; Montorsi F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2024 Aug; 22(4):102119. PubMed ID: 38852435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
    de Angelis M; Baudo A; Siech C; Jannello LMI; Di Bello F; Goyal JA; Tian Z; Longo N; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Gandaglia G; Moschini M; Montorsi F; Briganti A; Karakiewicz PI
    BJU Int; 2024 Oct; 134(4):602-607. PubMed ID: 38494989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sociodemographic and survival disparities for histologic variants of bladder cancer.
    Jue JS; Koru-Sengul T; Moore KJ; Miao F; Alameddine M; Nahar B; Punnen S; Parekh DJ; Ritch CR; Gonzalgo ML
    Can J Urol; 2018 Feb; 25(1):9179-9185. PubMed ID: 29524972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer.
    Takaoka EI; Miyazaki J; Ishikawa H; Kawai K; Kimura T; Ishitsuka R; Kojima T; Kanuma R; Takizawa D; Okumura T; Sakurai H; Nishiyama H
    Jpn J Clin Oncol; 2017 Jan; 47(1):67-73. PubMed ID: 27737963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.